Ribon Therapeutics
35 Cambridgepark Drive
Cambridge
MA
02140
United States
Tel: 617-914-8700
Website: https://ribontx.com/
Email: info@ribontx.com
38 articles about Ribon Therapeutics
-
Ribon Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
11/16/2020
Ribon Therapeutics to Present at the Piper Sandler 32 nd Annual Virtual Healthcare Conference
-
Ribon Therapeutics Announces the Appointment of Emma Reeve to the Company’s Board of Directors
11/9/2020
Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the appointment of Emma Reeve to its Board of Directors. Ms. Reeve will serve as Chair of the Audit Committee. “We welcome Emma to our board and look forward to engaging her diverse strategic financial and operational leadership experience,” said Jodie P. Morrison, Chair, B
-
Ribon Therapeutics Announces Appointment of Jodie P. Morrison as Chair of the Company’s Board of Directors
7/16/2020
Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, announced that Jodie P. Morrison has assumed the chair role of its board of directors, effective July 15, 2020.
-
Ribon Therapeutics Presents Additional Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and Demonstrates Broad Potential of its Platform at the AACR 2020 Virtual Meeting II
6/22/2020
Reinforces PARP7 as a novel therapeutic target and that inhibition of PARP7 induces both antitumor immunity and cancer cell-intrinsic effects
-
Ribon Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
5/26/2020
Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, announced that Victoria Richon, Ph.D., President and CEO, will provide a corporate overview and an update on the company’s lead clinical program, PARP7 inhibitor RBN-2397, at the Jefferies 2020 Virtual Healthcare Conference.
-
Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor - RBN-2397 - and its Discovery Platform at the Upcoming AACR 2020 Virtual Meeting II
5/15/2020
Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the presentation of new data at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II , taking place f
-
Ribon Therapeutics to Present at Upcoming Healthcare Conferences in May 2020
5/4/2020
Ribon Therapeutics announced that Victoria Richon, Ph.D., President and CEO, will present at two upcoming virtual healthcare conferences. Presentations will consist of a panel discussion and a corporate overview..
-
In the midst of a pandemic, oncology-focused companies virtually unveil data at the American Association for Cancer Research (AACR) Annual Meeting.
-
Ribon Therapeutics Presents Preclinical Data from its PARP7 and PARP14 Programs at AACR Virtual Meeting I
4/27/2020
Lead program, PARP7 inhibitor RBN-2397, demonstrates complete tumor regression in preclinical cancer models
-
Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings
4/14/2020
Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the presentation of new data at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place from April 27-28, 2020.
-
Ribon Therapeutics to Present at Upcoming Scientific Conferences
1/24/2020
Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, today announced it will be presenting at two upcoming scientific conferences.
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
Ribon Therapeutics Strengthens Scientific Advisory Board with Appointment of Neal Rosen, M.D., Ph.D.
12/18/2019
Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, today announced the appointment of Neal Rosen, M.D., Ph.D., to its scientific advisory board (SAB).
-
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor
9/4/2019
PARP7 is a Novel Tumor Dependency, Enabling Cancer Cells to Evade the Immune System First Ever Clinical Evaluation of a monoPARP Inhibitor
-
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer
8/6/2019
Mr. Stewart brings more than 20 years of executive experience in the biotechnology area with a focus on business development, strategy and commercialization.
-
1Q2019 Life Science Growth Announcements
4/18/2019
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry. -
On opposite sides of the country, the two new companies tackle different methods to treat disease.
-
Led By Ex-Sanofi Exec, Mysterious Ribon Therapeutics Eyes a New Type of Cancer Drug
3/4/2016